GENinCode plc (AIM: GENI.L), a genetics company focused on the prevention of cardiovascular disease (“CVD”) and the early detection of ovarian cancer, announced on 14 February 2025 the launch of a fundraising comprising a
hVIVO PLC (AIM:HVO) £2m hMPV characterisation study contract
hVIVO plc (AIM: HVO), a fast-growing early-stage Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that, following the success of its pilot human metapneumovirus
Celadon Pharmaceuticals PLC (AIM:CEL) soared over 25% after finance update
Shares in Celadon Pharmaceuticals PLC (AIM: CEL), a UK-based pharmaceutical company specialising in cannabis-based medicines, surged over 25% in early trading following a financial update.
Belluscura PLC (AIM:BELL) Launch of WRAP Retail Offer to raise up to £0.5 million
Belluscura plc (AIM: BELL), a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies, is pleased to announce a retail offer (the “WRAP Retail Offer”) via the
Ananda Pharma plc (AQSE: ANA) Appointment of Commercial Adviser
Ananda Pharma plc (AQSE: ANA), a UK company focused on the development of cannabinoid therapies targeting the treatment of complex, chronic inflammatory pain conditions is pleased to announce the appointment of Andy Rust as
Faron Pharmaceuticals Ltd (AIM:FARN) Results of Oversubscribed Placing
Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces that the Bookbuild, announced on 5 February 2025, is now closed.
hVIVO PLC (AIM:HVO) Shionogi reports positive RSV trial results
Shionogi reports positive results from RSV antiviral human challenge trial conducted by hVIVO Human challenge trials provide valuable insights to accelerate candidate development
hVIVO PLC (AIM:HVO) RSV contract signed with Inhalon Biopharma
RSV human challenge trial contract signed with new client, Inhalon Biopharma
Fusion Antibodies (AIM:FAB) OptiMAL R&D Update
OptiMAL® R&D Update
Novacyt S.A. (AIM:NCYT) Full year trading update
Paris, France, and Manchester, UK – 30 January 2025 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces an unaudited full year
Poolbeg Pharma PLC (AIM:POLB) Offer Update – Extension to PUSU Deadline
Combination of Poolbeg and HOOKIPA Pharma Inc. Offer Update – Extension to PUSU Deadline
Angle PLC (AIM:AGL) Analysis of CTC-DNA and ctDNA using Illumina assay
ANGLE PLC (AIM: AGL, OTCQX: ANPCY) has revealed new research indicating that analysing entire tumour cells in the bloodstream, rather than solely DNA fragments, may offer a more comprehensive understanding